Articles & Video
The Future of the Global Pharmaceutical Regulatory Affairs Industry
In a new interactive ebook, we take a deep dive into the challenges and trends we may see in pharmaceutical regulatory affairs over the next decade.
Pharma and Medical Device Regulations Content Library: Whitepapers and Reports Collection
Explore our collection of exclusive whitepapers and reports covering the hottest topics in pharma, biotech and medical device regulatory affairs and law with one simple registration.
The biggest breakthroughs in life sciences the last 10 years
CRISPR, CAR-T, immunotherapies, genome sequencing, AI - what is the biggest breakthrough in the life sciences in the last 10 years?
Brazil & LATAM Pharmaceutical Regulations: Global Harmonisation & the Impact of Covid-19
We speak to two industry experts about how Brazil and LATAM region is working toward global regulatory harmonisation.
Diversity in the life sciences workplace: Implementing a leading corporate culture for innovation - WHITEPAPER
This paper looks at how to foster racial, gender, geographical, neuro and cognitive diversity in the life sciences to achieve an inclusive culture built for innovation.
REPORT: Diversity, Inclusion and Sustainability in the Global Life Sciences Industry 2020
Diversity and Inclusion in Life Sciences 2020: Research analysis of how life sciences professionals around the world view representation of women and minorities in the industry, plus the importance of sustainability.
The Future of IDMP: Quick Fire Questions with the Experts
We spoke to five experts from across regulatory information management about IDMP, the impact of COVID-19 and common obstacles.
Global Pharmaceutical Regulatory Affairs Digital Week offers live practical advice
From future RIM to implementing IDMP, we take a first look at the insightful sessions of the new webinar series coming 24 June.
COVID-19: Advice from the legal experts
We asked legal experts for their best tips and advice for pharmaceutical organisations during the COVID-19 pandemic.
Looking to 2030 Report: The Future of the Global Life Sciences and Pharma Industry
This exclusive report looks at predictions for how the global life sciences and pharma industry will change over the coming decade.
COVID-19 Report: The Response to and Impacts on the Global Life Sciences Industry
COVID-19 Report: How is the life sciences industry developing a vaccine, treatment and testing for COVID-19 and what impact is it having on supply chain?
Industry Report: Global Pharmaceutical Regulatory Affairs 2020
From data handling to language barriers, our latest report reveals the challenges pharma professionals are facing in regulatory processes around the world today.
Life Sciences in 2030 Survey: Complete to win a 2-day conference pass
We are a conducting a huge survey of life sciences professionals around the world on how the industry will look by 2030. Complete it here to get early access to the final report.
The use of Real World Evidence and AI within the regulatory landscape
This whitepaper explores how the pharmaceutical industry can leverage Real World Evidence and AI in regulatory affairs.
Building a global regulatory strategy
This whitepaper identifies the key factors, requirements and challenges affecting applying for marketing authorisation in different world regions.
The 2020 Outlook for Europe
Discover insights and gain helpful advice in this curated article pack from Informa Pharma Intelligence on biotech, regulations, pharma, and financial investment in Europe and the United Kingdom.
Global Pharmaceutical Regulatory Affairs State of the Industry Report 2019
In early 2019, we surveyed the perspectives of pharmaceutical regulatory professionals around the world. This report reveals insights into the industry's greatest challenges.
China's changing pharmaceutical regulatory approval landscape
China has recently taken unprecedented steps to improve its healthcare and regulatory system. This whitepaper examines the recent changes and what opportunities and challenges they bring.
Regulatory challenges and strategies for oligonucleotide, peptide and mRNA therapeutics - WHITEPAPER
We explore the regulatory challenges and successful approval strategies for oligonucleotide, peptide and mRNA therapeutics.
Regulatory development opportunities for global harmonisation of eSubmissions
What's delaying the global harmonisation of eSubmissions for market authorisation? This whitepaper examines the latest developments and ongoing challenges.
Digital Health: Advancing innovation through technology and strategic partnerships
Insights from investors, biopharma leaders and digital health executives on how to navigate the digital health sector as it transforms every aspect of the pharmaceutical value chain.